Search Results - Panayiotis Panayiotidis

  • Showing 1 - 12 results of 12
Refine Results
  1. 1
    mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3- mutated acute myeloid leukemia cells

    mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3- mutated acute myeloid leukemia cells by Weina Chen, Ηλίας Δράκος, Ioannis Grammatikakis, Ellen Schlette, Li Jiang, Vasiliki Leventaki, Efi Staikou-Drakopoulou, Efstratios Patsouris, Panayiotis Panayiotidis, L. Jeffrey Medeiros, George Z. Rassidakis

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Thalidomide and dexamethasone combination for refractory multiple myeloma

    Thalidomide and dexamethasone combination for refractory multiple myeloma by Meletios Α. Dimopoulos, Konstantinos Zervas, G. Kouvatseas, Eleni Galani, Vassiliki Grigoraki, Christos Kiamouris, E. Vervessou, E. Samantas, C Papadimitriou, Olga Economou, Dimitra Gika, Panayiotis Panayiotidis, Ioannis Christakis, Nicolaos Anagnostopoulos

    Published 2001
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

    Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib by Pier Luigi Zinzani, Muhi̇t Özcan, Marcelo Capra, Armando Santoro, Panayiotis Panayiotidis, Krimo Bouabdallah, Wojciech Jurczak, Charles Phelps, Florian Hiemeyer, Lidia Mongay Soler, J. Garcia‐Vargas, Barrett H. Childs, Georg Lenz, Matthew J. Matasar, Martin Dreyling

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

    Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma by Pier Luigi Zinzani, Armando Santoro, Luigina Mollica, Sirpa Leppä, George Follows, Georg Lenz, Won Seog Kim, Arnon Nagler, Panayiotis Panayiotidis, Judit Demeter, Franck Morschhauser, Liana Rodrigues, John A. Reeves, Florian Hiemeyer, Ashok Miriyala, J. Garcia‐Vargas, Barrett H. Childs, Martin Dreyling

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study

    Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study by Evangelos Terpos, Maria Gavriatopoulou, Despina Fotiou, Chara Giatra, Ioannis Asimakopoulos, Maria Dimou, Aimilia D. Sklirou, Ioannis Ntanasis‐Stathopoulos, Ismini Darmani, Αlexandros Briasoulis, Efstathios Kastritis, Maria K. Angelopoulou, Ioannis Baltadakis, Panayiotis Panayiotidis, Ioannis P. Trougakos, Theodoros P. Vassilakopoulos, Maria Pagoni, Meletios Α. Dimopoulos

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6‐year follow‐up of CHRONOS‐1

    Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6‐year follow‐up of CHRONOS‐1 by Martin Dreyling, Armando Santoro, Luigina Mollica, Sirpa Leppä, George Follows, Georg Lenz, W. S. Kim, Arnon Nagler, Panayiotis Panayiotidis, Judit Demeter, Muhi̇t Özcan, Marina Kosinova, Mariano Provencio, Massimo Magagnoli, Krimo Bouabdallah, Dae Seog Heo, Colin Phipps Diong, Javier Muñoz, A. Cao, Florian Hiemeyer, Florence Odongo, J. Garcia‐Vargas, Barrett H. Childs, Pier Luigi Zinzani

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

    Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial by Andrew H. Wei, Pau Montesinos, Vladimir Ivanov, Courtney D. DiNardo, Jan Novák, Kamel Laribi, Inho Kim, Don A. Stevens, Walter Fiedler, Maria Pagoni, Olga Samoilova, Yu Hu, Αchilles Anagnostopoulos, Julie Bergeron, Jing‐Zhou Hou, Vidhya Murthy, Takahiro Yamauchi, Andrew McDonald, Brenda Chyla, Sathej Gopalakrishnan, Qi Jiang, Wellington Mendes, John Hayslip, Panayiotis Panayiotidis

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care

    Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care by Theodoros P. Vassilakopoulos, Gerassimos A. Pangalis, Andreas Katsigiannis, Sotirios G. Papageorgiou, Nikos Constantinou, Evangelos Terpos, Alexandra Zorbala, Effimia Vrakidou, Panagiotis Repoussis, Christos Poziopoulos, Zacharoula Galani, Maria Dimopoulou, Styliani Kokoris, Sotirios Sachanas, Christina Kalpadakis, Evagelia M. Dimitriadou, Marina P. Siakantaris, Marie‐Christine Kyrtsonis, John Dervenoulas, Meletios Α. Dimopoulos, John Meletis, Paraskevi Roussou, Panayiotis Panayiotidis, Photis Beris, Maria K. Angelopoulou

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

    Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia by Keith W. Pratz, Panayiotis Panayiotidis, Christian Récher, Xudong Wei, Brian A. Jonas, Pau Montesinos, Vladimir Ivanov, Andre C. Schuh, Courtney D. DiNardo, Jan Novák, Vlatko Pejša, Don A. Stevens, Su‐Peng Yeh, Inho Kim, Mehmet Turgut, Nicola Fracchiolla, Kazuhito Yamamoto, Yishai Ofran, Andrew H. Wei, Cat N. Bui, Katy Benjamin, Rajesh Kamalakar, Jalaja Potluri, Wellington Mendes, Jacob Devine, Walter Fiedler

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial

    Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial by Arnon P. Kater, Önder Arslan, Fatih Demırkan, Yair Herishanu, Burhan Ferhanoğlu, Marcos González, Brian Leber, Marco Montillo, Panayiotis Panayiotidis, Davide Rossi, Alan P Skarbnik, Adrian Tempescul, Mehmet Turgut, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Stuart Lanham, Benjamin Sale, Luis Del Rio, Relja Popovic, Brenda Chyla, Todd Busman, Viktor Komlósi, Xifeng Wang, Kavita Sail, Germán Peña, Tamas Vizkelety, Francesco Forconi

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    <i>BTK</i> and <i>PLCG2</i> remain unmutated in one-third of patients with CLL relapsing on ibrutinib

    <i>BTK</i> and <i>PLCG2</i> remain unmutated in one-third of patients with CLL relapsing on ibrutinib by Silvia Bonfiglio, Lesley‐Ann Sutton, Viktor Ljungström, Antonella Capasso, Tatjana Pandzic, Simone Weström, Hassan Foroughi Asl, Aron Skaftason, Anna Gellerbring, Anna Lyander, Francesca Gandini, Gianluca Gaïdano, Livio Trentin, Lisa Bonello, Gianluigi Reda, Csaba Bödör, Niki Stavroyianni, Constantine S. Tam, Roberto Marasca, Francesco Forconi, Panayiotis Panayiotidis, Ingo Ringshausen, Ozren Jakšić, Anna Maria Frustaci, Sunil Iyengar, Marta Coscia, Stephen P. Mulligan, Loïc Ysebaert, Владимир Стругов, Carolina Pavlovsky, Renata Walewska, Anders Österborg, Diego Cortese, Pamela Ranghetti, Panagiotis Baliakas, Κώστας Σταματόπουλος, Lydia Scarfò, Richard W. Rosenquist, Paolo Ghia

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact

    Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact by Panagiotis Baliakas, Sabine Jeromin, Michalis Iskas, Anna Puiggros, Karla Plevová, Florence Nguyen‐Khac, Zadie Davis, Gian Matteo Rigolin, Andrea Visentin, Aliki Xochelli, Julio Delgado, Fanny Baran‐Marszak, Evangelia Stalika, Pau Abrisqueta, Kristina Ďurechová, George Papaioannou, Virginie Éclache, Maria Dimou, Theodoros Iliakis, Rosa Collado, Michael Doubek, Marı́a José Calasanz, Neus Ruiz‐Xivillé, Carolina Moreno, Marie Jarošová, Alexander C. Leeksma, Panayiotis Panayiotidis, Helena Podgornik, Florence Cymbalista, Αchilles Anagnostopoulos, Livio Trentin, Niki Stavroyianni, Fred Davi, Paolo Ghia, Arnon P. Kater, Antonio Cuneo, Šárka Pospı́šilová, Blanca Espinet, Anastasia Athanasiadou, David Oscier, Claudia Haferlach, Κώστας Σταματόπουλος

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: